Ensign Peak Advisors Inc Sells 46,164 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ensign Peak Advisors Inc decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,173,495 shares of the medical research company’s stock after selling 46,164 shares during the quarter. Thermo Fisher Scientific comprises 1.2% of Ensign Peak Advisors Inc’s holdings, making the stock its 13th largest position. Ensign Peak Advisors Inc’s holdings in Thermo Fisher Scientific were worth $648,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of TMO. Accretive Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock worth $340,000 after buying an additional 48 shares during the period. Aveo Capital Partners LLC lifted its position in Thermo Fisher Scientific by 9.7% in the fourth quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock valued at $433,000 after purchasing an additional 72 shares during the last quarter. Gryphon Financial Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 8.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock worth $794,000 after purchasing an additional 116 shares during the last quarter. TrinityPoint Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. TrinityPoint Wealth LLC now owns 4,080 shares of the medical research company’s stock worth $2,166,000 after buying an additional 164 shares during the period. Finally, SageView Advisory Group LLC boosted its position in Thermo Fisher Scientific by 11.3% during the 4th quarter. SageView Advisory Group LLC now owns 3,532 shares of the medical research company’s stock valued at $2,003,000 after buying an additional 359 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Down 1.1 %

Thermo Fisher Scientific stock opened at $613.69 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $627.88. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The business’s fifty day simple moving average is $599.56 and its two-hundred day simple moving average is $581.47. The company has a market capitalization of $234.26 billion, a price-to-earnings ratio of 39.36, a price-to-earnings-growth ratio of 2.86 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $5.15 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TMO. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Wells Fargo & Company began coverage on Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price objective for the company. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $767.00 price target on shares of Thermo Fisher Scientific in a report on Friday. Finally, Barclays decreased their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $647.78.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares in the company, valued at $10,747,403.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The disclosure for this sale can be found here. Insiders sold 23,084 shares of company stock worth $14,094,292 over the last quarter. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.